Monocytes from Sjögren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis

Clinical and Experimental Immunology

Volumn 177, Issue 3, 2014, Pages 662-670

  Hauk, V ^a   Fraccaroli, L ^a   Grasso, E ^a   Eimon, A ^b   Ramhorst, R ^a   Hubscher, O ^b   Perez Leiros C ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b CEMIC   (Argentina)

Author keywords

Apoptotic cell clearance; Monocytes; Sj gren's syndrome patients; VPAC receptors

Indexed keywords

HYDROXYCHLOROQUINE; LEVOTHYROXINE; LIPOPOLYSACCHARIDE; PILOCARPINE; PREDNISONE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL ISOLATION; CELL PHAGOCYTOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SJOEGREN SYNDROME; SYSTEMIC THERAPY;

APOPTOTIC CELL CLEARANCE; MONOCYTES; SJÖGREN'S SYNDROME PATIENTS; VPAC RECEPTORS;

ADULT; AGED; APOPTOSIS; CASE-CONTROL STUDIES; CYTOPHAGOCYTOSIS; GENE EXPRESSION REGULATION; HUMANS; LIPOPOLYSACCHARIDES; MIDDLE AGED; MONOCYTES; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; SJOGREN'S SYNDROME; VASOACTIVE INTESTINAL PEPTIDE; YOUNG ADULT;

EID: 84904737849     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12378     Document Type: Article

References (49)

1. García-Carrasco M, Fuentes-Alexandro S, Escárcega RO, Salgado G, Riebeling C, Cervera R. Pathophysiology of Sjögren's syndrome. Arch Med Res 2006; 37:921-932.
2. Meijer JM, Meiners PM, Vissink A etal. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:960-968.
3. Konttinen YT, Fuellen G, Bing Y etal. Sex steroids in Sjögren's syndrome. J Autoimmun 2012; 39:49-56.
4. Tzioufas AG, Vlachoyiannopoulos PG. Sjogren's syndrome: an update on clinical, basic and diagnostic therapeutic aspects. J Autoimmun 2012; 39:1-3.
5. Vitali C, Bootsma H, Bowman SJ etal. Classification criteria for Sjogren's syndrome: we actually need to definitively resolve the long debate on the issue. Ann Rheum Dis 2013; 72:476-478.
6. Rosignoli F, Roca V, Meiss R, Leceta J, Gomariz RP, Pérez Leirós C. Defective signalling in salivary glands precedes the autoimmune response in the non-obese diabetic mouse model of sialadenitis. Clin Exp Immunol 2005; 142:411-418.
7. Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM. Sjögren's syndrome: why autoimmune epithelitis? Oral Dis 2006; 12:523-532.
8. Manoussakis MN, Kapsogeorgou EK. The role of intrinsic epithelial activation in the pathogenesis of Sjögren's syndrome. J Autoimmun 2010; 35:219-224.
9. Rosignoli F, Goren NB, Perez Leiros C. Alterations in nitric oxide synthase activity and expression in submandibular glands of NOD mice. Clin Immunol 2001; 101:86-93.
10. Nguyen KH, Brayer J, Cha S etal. Evidence for anti-muscarinic acetylcholine receptor antibody-mediated secretory dysfunction in NOD mice. Arthritis Rheum 2000; 43:2297-2306.
11. Barrera MJ, Bahamondes V, Sepúlveda D etal. Sjögren's syndrome and the epithelial target: a comprehensive review. J Autoimmun 2013; 42:7-18.
12. Robinson CP, Yamachika S, Alford CE etal. Elevated levels of cysteine protease activity in saliva and salivary glands of the nonobese diabetic (NOD) mouse model for Sjögren syndrome. Proc Natl Acad Sci USA 1997; 94:5767-5771.
13. Calafat M, Larocca L, Roca V etal. Vasoactive intestinal peptide inhibits TNF-alpha-induced apoptotic events in acinar cells from nonobese diabetic mice submandibular glands. Arthritis Res Ther 2009; 11:R53.
14. Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome. Nat Rev Rheumatol 2010; 6:529-537.
15. Jonsson R, Vogelsang P, Volchenkov R, Espinosa A, Wahren-Herlenius M, Appel S. The complexity of Sjögren's syndrome: novel aspects on pathogenesis. Immunol Lett 2011; 141:1-9.
16. Kong L, Robinson CP, Peck AB etal. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin Exp Rheumatol 1998; 16:675-681.
17. Nguyen CQ, Cornelius JG, Cooper L etal. Identification of possible candidate genes regulating Sjögren's syndrome-associated autoimmunity: a potential role for TNFSF4 in autoimmune exocrinopathy. Arthritis Res Ther 2008; 10:R137-R137.
18. Fadok VA, Bratton D, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101:890-898.
19. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5:953-964.
20. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-969.
21. Carlin LM, Stamatiades EG, Auffray C etal. Nr4a1-dependent ly6c(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell 2013; 153:362-375.
22. Gaipl US, Voll R, Sheriff A, Franz S, Kalden JR, Herrmann M. Impaired clearance of dying cells in systemic lupus erythematosus. Autoimmun Rev 2005; 4:189-194.
23. Shao WH, Cohen P. Disturbances of apoptotic cell clearance in systemic lupus erythematosus. Arthritis Res Ther 2011; 13:202.
24. Baumann I, Kolowos W, Voll RE etal. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46:191-201.
25. Stoffels K, Overbergh L, Giulietti A etal. NOD macrophages produce high levels of inflammatory cytokines upon encounter of apoptotic or necrotic cells. J Autoimmun 2004; 23:9-15.
26. Hauk V, Calafat M, Larocca L etal. Vasoactive intestinal peptide/vasoactive intestinal peptide receptor relative expression in salivary glands as one endogenous modulator of acinar cell apoptosis in a murine model of Sjögren's syndrome. Clin Exp Immunol 2011; 166:309-316.
27. Larocca L, Hauk V, Calafat M etal. Modulation of macrophage inflammatory profile in pregnant nonobese diabetic (NOD) mice. Mol Cell Endocrinol 2011; 333:112-118.
28. Delgado M, Munoz-Elias E, Kan Y etal. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-KB and cAMP response element-binding protein/c-Jun. J Biol Chem 1998; 273:31427-31436.
29. Dorsam G, Voice J, Kong Y, Goetzl EJ. Vasoactive intestinal peptide mediation of development and functions of T lymphocytes. Ann NY Acad Sci 2000; 921:79-91.
30. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7:563-568.
31. Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 2003; 170:308-314.
32. Gomariz RP, Arranz A, Juarranz Y etal. Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides 2007; 28:1825-1832.
33. Arranz A, Abad C, Juarranz Y, Leceta J, Martinez C, Gomariz RP. Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 2008; 15:46-53.
34. Rosignoli F, Torroba M, Juarranz Y etal. VIP and tolerance induction in autoimmunity. Ann NY Acad Sci 2006; 1070:525-530.
35. Tan YV, Waschek JA. Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. ASN Neuro 2011; 3:pii: e00065.
36. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007; 13:241-251.
37. Pozo D, Gonzalez-Rey E, Chorny A, Anderson P, Varela N, Delgado M. Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides 2007; 28:1833-1846.
38. Lodde BM, Mineshiba F, Wang J etal. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006; 65:195-200.
39. Larocca L, Calafat M, Roca V, Franchi AM, Pérez Leiros C. VIP limits LPS-induced nitric oxide production through IL-10 in NOD mice macrophages. Int Immunopharmacol 2007; 7:1343-1349.
40. Vitali C, Bombardieri S, Jonsson R etal. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554-558.
41. Aframian DJ, Cukierman E, Nikolovski J, Mooney DJ, Yamada KM, Baum BJ. The growth and morphological behavior of salivary epithelial cells on matrix protein-coated biodegradable substrata. Tissue Eng 2000; 6:209-216.
42. Herrera JL, Gonzalez-Rey E, Fernandez-Montesinos R, Quintana FJ, Najmanovich R, Pozo D. Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages. J Cell Mol Med 2009; 13:3209-3217.
43. Tas SW, Quartier P, Botto M, Fossati-Jimack L. Macrophages from patients with SLE and rheumatoid arthritis have defective adhesion in vitro, while only SLE macrophages have impaired uptake of apoptotic cells. Ann Rheum Dis 2006; 65:216-221.
44. Abad C, Tan YV, Lopez R etal. Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2010; 107:19555-19560.
45. Abad C, Tan YV, Cheung-Lau G, Nobuta H, Waschek J. VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses. PLOS ONE 2012; 7:e36922.
46. Lara-Marquez M, O'Dorisio M, O'Dorisio T, Shah M, Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol 2001; 166:2522-2530.
47. Couvineau A, Laburthe M. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol 2012; 166:42-50.
48. Juarranz Y, Gutiérrez-Cañas I, Santiago B, Carrión M, Pablos JL, Gomariz RP. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum 2008; 58:1086-1095.
49. Carrión M, Juarranz Y, Pérez-García S etal. RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. Arthritis Rheum 2011; 63:1626-1636.